A
Arvind Remedies
ARVINDREM
Arvind Remedies
Healthcare Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -6.73% over last 3 years.
- Company has high debtors of 221 days.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
-98% lower than
3Y
Net Income Growth
32%
Quarterly Results
| Particulars | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 220 | 233 | 274 | 259 | 293 | 176 | 47 | 12 | 6 | 2 | 2 | 1 |
| Expenses | 144 | 182 | 187 | 222 | 195 | 251 | 197 | 172 | 14 | 6 | 2 | 98 | 2 |
| Operating Profit | 40 | 38 | 46 | 53 | 63 | 42 | -21 | -126 | -2 | 1 | 0 | -95 | 0 |
| OPM % | 22% | 17% | 20% | 19% | 25% | 14% | -12% | -269% | -14% | 10% | 1% | -3881% | -21% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | -115 | -67 | 0 | 0 | 0 | 4 | -20 |
| Interest | 16 | 17 | 18 | 26 | 24 | 33 | 22 | -5 | -4 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 4 | 7 | 6 | 7 | 4 | 6 | 6 | 1 | 7 | 6 |
| PBT | 21 | 18 | 25 | 23 | 33 | 2 | -165 | -191 | -4 | -6 | -2 | -99 | -26 |
| Tax % | 23% | 26% | 24% | 53% | 20% | 40% | 0% | -3% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 17 | 13 | 19 | 11 | 26 | 1 | -165 | -185 | -4 | -6 | -2 | -99 | -26 |
| EPS in Rs | 0.34 | 1.93 | 2.73 | 1.56 | 3.83 | 0.19 | -24.18 | -27.19 | -0.62 | -0.89 | -0.22 | -14.55 | -3.82 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 15m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 157 | 176 | 218 | 298 | 363 | 437 | 664 | 911 | 787 | 12 |
| Expenses | 133 | 143 | 160 | 198 | 267 | 321 | 369 | 531 | 734 | 842 | 107 |
| Operating Profit | 11 | 14 | 16 | 20 | 31 | 41 | 68 | 134 | 177 | -55 | -95 |
| OPM % | 7% | 9% | 9% | 9% | 10% | 11% | 16% | 20% | 19% | -7% | -777% |
| Other Income | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -170 | -16 |
| Interest | 5 | 7 | 7 | 11 | 14 | 16 | 28 | 59 | 77 | 71 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 13 | 14 | 29 | 20 |
| PBT | 5 | 5 | 7 | 7 | 15 | 23 | 37 | 63 | 86 | -325 | -133 |
| Tax % | 39% | 20% | 26% | 33% | 31% | 26% | 48% | 35% | 32% | -2% | — |
| Net Profit | 3 | 4 | 5 | 5 | 11 | 17 | 19 | 41 | 59 | -320 | -133 |
| EPS in Rs | — | — | — | — | — | 0.35 | 0.4 | 0.84 | 8.65 | -46.98 | -19.48 |
| Div. Payout % | 42% | 30% | 25% | 27% | 12% | 20% | 17% | 12% | 9% | 0% | — |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 26 | 26 | 26 | 26 | 26 | 48 | 48 | 48 | 68 | 68 |
| Reserves | 12 | 15 | 19 | 22 | 69 | 73 | 95 | 146 | 211 | -110 |
| Borrowings | 57 | 85 | 86 | 104 | 123 | 184 | 362 | 520 | 623 | 750 |
| Other Liabilities | 22 | 31 | 42 | 40 | 50 | 65 | 98 | 128 | 189 | 77 |
| Total Liabilities | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1,092 | 784 |
| Fixed Assets | 26 | 29 | 30 | 35 | 36 | 45 | 242 | 251 | 349 | 275 |
| CWIP | 5 | 27 | 35 | 20 | 38 | 19 | 49 | 37 | 67 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 3 |
| Other Assets | 86 | 102 | 108 | 138 | 194 | 306 | 309 | 551 | 670 | 505 |
| Total Assets | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1,092 | 784 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -9 | 10 | 16 | -13 | -8 | 12 | 7 | 13 | -60 | -151 |
| Investing | -7 | -27 | -12 | 8 | -21 | -62 | -158 | -123 | -21 | 105 |
| Financing | 7 | 20 | -8 | 5 | 42 | 55 | 152 | 112 | 63 | 44 |
| Net Cash Flow | -9 | 4 | -3 | 0 | 13 | 6 | 1 | 2 | -18 | -2 |
| Free Cash Flow | -16 | -16 | 4 | -5 | -29 | -50 | -149 | -108 | -79 | -39 |
| CFO/OP | -76 | 80 | 107 | -60 | -18 | 46 | 19 | 19 | -31 | 276 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135 | 152 | 143 | 140 | 131 | 135 | 142 | 133 | 133 | 221 |
| Inventory Days | 66 | 75 | 78 | 65 | 66 | 68 | 92 | 89 | 104 | 3 |
| Days Payable | 23 | 47 | 69 | 50 | 48 | 49 | 40 | 49 | 50 | 4 |
| Cash Conversion Cycle | 178 | 179 | 152 | 155 | 149 | 155 | 194 | 173 | 187 | 221 |
| Working Capital Days | 178 | 170 | 149 | 176 | 171 | 162 | 174 | 177 | 206 | 214 |
| ROCE % | — | 11% | 11% | 13% | 16% | 15% | 16% | 20% | 20% | -9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Arvind Remedies insights
64 extracted metrics + investor summaries across FY06–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Newspaper Publication
9h - Of Newspaper Advertisement for the dispatch of Postal Ballot Notice. 9h - Of Newspaper Advertisement for the dispatch of Postal Ballot Notice.
2
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11 Feb - Of Transcript of Earnings Conference Call for the quarter and nine months ended December 31, 2025 11 Feb - Of Transcript of Earnings Conference Call for the quarter and nine months ended December 31, 2025
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Feb - Investor/analyst meeting on Feb 16, 2026 hosted by Spark Capital; in-person in Mumbai. 10 Feb - Investor/analyst meeting on Feb 16, 2026 hosted by Spark Capital; in-person in Mumbai.
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Feb - Newspaper Publication of Financial Results for quarter and nine months ended December 31, 2025. 9 Feb - Newspaper Publication of Financial Results for quarter and nine months ended December 31, 2025.
5
Announcement Of Equity Infusion In Our Wholly Owned Subsidiary Based In Singapore
6 Feb - Approved Q3/9M results; EUR 3M equity infusion to Singapore subsidiary; independent director change Feb 06, 2026. 6 Feb - Approved Q3/9M results; EUR 3M equity infusion to Singapore subsidiary; independent director change Feb 06, 2026.
Frequently Asked Questions about Arvind Remedies
What does Arvind Remedies Ltd do?
Arvind Remedies (ARL) engages in the drugs and pharmaceuticals business of India that manufactures capsules, liquids, ointments, tablets Syrup, Cream & Powders as well as Ayurvedic products at Kancheepuram in Tamilnadu.
Which sector does Arvind Remedies Ltd belong to?
Arvind Remedies Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Arvind Remedies (ARL) engages in the drugs and pharmaceuticals business of India that manufactures capsules, liquids, ointments, tablets Syrup, Cream & Powders as well as Ayurvedic products at Kancheepuram in Tamilnadu.
Website arvindremedies.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ARVINDREM.md for Arvind Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.